HENLIUS (02696): NMPA Approves Phase 1b/2 Clinical Trial Application for HLX43 Injection Combined with HLX07 in Advanced/Metastatic Solid Tumors

Stock News
09/30

HENLIUS (02696) announced that the National Medical Products Administration (NMPA) has recently approved its Phase 1b/2 clinical trial application for HLX43 injection (PD-L1-targeted antibody-drug conjugate) in combination with HLX07 (recombinant anti-EGFR humanized monoclonal antibody injection) for the treatment of advanced/metastatic solid tumors.

HLX43 represents a PD-L1-targeted antibody-drug conjugate (ADC) developed by the company through conjugating a licensed novel DNA topoisomerase I inhibitor small molecule toxin-peptide linker with its proprietary PD-L1-targeting antibody, intended for treating advanced/metastatic solid tumors. HLX07 is an innovative biological drug independently developed by the company targeting the EGFR pathway, planned for advanced solid tumor treatment.

In February 2023, Phase 1b/2 clinical study results of HLX07 combined with chemotherapy for advanced solid tumor treatment demonstrated favorable safety and tolerability profiles. Currently, multiple Phase 2 clinical studies involving HLX07 are being conducted within China, primarily including a Phase 2 clinical trial of HLX07 monotherapy for treating advanced cutaneous squamous cell carcinoma (CSCC) and other solid tumors, as well as a Phase 2 clinical trial of Hansizhuang® combined with HLX07 for treating advanced or metastatic squamous non-small cell lung cancer (sqNSCLC) and other solid tumors.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10